NCT03750864 is a NA clinical trial of ACT-LCS Therapy in Lung Cancer Stigma, sponsored by University of Arizona.

Who is sponsoring NCT03750864?

NCT03750864 is sponsored by University of Arizona.

What drugs are being tested in NCT03750864?

Interventions in NCT03750864: ACT-LCS Therapy.

What condition does NCT03750864 study?

NCT03750864 studies Lung Cancer Stigma, Lung Cancer, Stigma, Social, Stigmatization, Acceptance Processes.

Is NCT03750864 still recruiting?

NCT03750864 is currently completed. Last updated 28 July 2022.

Last reviewed 2022-07-28 · How we verify

NCT03750864

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Innovative Approach to Reduce Lung Cancer Stigma

Completed NA Last updated 28 July 2022

What this trial tests

NA trial testing ACT-LCS Therapy in Lung Cancer Stigma in 24 participants. Completed in 13 July 2020.

Timeline

27 October 2018

Primary endpoint
13 July 2020

13 July 2020

Quick facts

Lead sponsor	University of Arizona
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	supportive care
Enrollment	24
Start date	27 October 2018
Primary completion	13 July 2020
Estimated completion	13 July 2020
Sites	2 locations across United States

Drugs / interventions tested

ACT-LCS Therapy

Conditions studied

Lung Cancer Stigma — all drugs for Lung Cancer Stigma →
Lung Cancer — all drugs for Lung Cancer →
Stigma, Social — all drugs for Stigma, Social →
Stigmatization — all drugs for Stigmatization →

Sponsor

University of Arizona

Who can join

18 and older, any sex, with Lung Cancer Stigma or Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a feasibility study examining the feasibility and acceptability of a novel psychotherapy intervention on lung cancer patients who are experiencing stigma.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other University of Arizona trials

Trials by the same sponsor.

NCT04062890 — Inhibiting GABA Transaminase to Relieve Obesity Induced Hyperinsulinemia and Insulin Resistance · Phase 2 · withdrawn
NCT05569486 — Elucidating the Central Mechanisms of Action for Green Light Therapy in Managing Chronic Pain · NA · not yet recruiting
NCT05064111 — Utility of Adding MR Fusion to Standard US Guided Prostate Biopsy · suspended
NCT06567899 — Mechanistic Underpinnings of Preeclampsia · not yet recruiting
NCT07254793 — Prophylactic and Therapeutic DLI-X for Leukemia Relapse After HCT · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03750864 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Arizona
Last refreshed: 28 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03750864.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing